Literature DB >> 26091341

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.

Felix Y Feng1, Johann S de Bono2, Mark A Rubin3, Karen E Knudsen4.   

Abstract

Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recently shown to have potential clinical impact in a number of disease settings, particularly as related to cancer therapy, treatment for cardiovascular dysfunction, and suppression of inflammation. The molecular basis for PARP1 inhibitor function is complex, and appears to depend on the dual roles of PARP1 in DNA damage repair and transcriptional regulation. Here, the mechanisms by which PARP-1 inhibitors elicit clinical response are discussed, and strategies for translating the preclinical elucidation of PARP-1 function into advances in disease management are reviewed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091341      PMCID: PMC4487541          DOI: 10.1016/j.molcel.2015.04.016

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  79 in total

1.  Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors:  Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-01-30       Impact factor: 12.531

Review 2.  The recognition and removal of cellular poly(ADP-ribose) signals.

Authors:  Eva Barkauskaite; Gytis Jankevicius; Andreas G Ladurner; Ivan Ahel; Gyula Timinszky
Journal:  FEBS J       Date:  2013-06-18       Impact factor: 5.542

3.  The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1.

Authors:  W J Chang; R Alvarez-Gonzalez
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

4.  PARP-3 and APLF function together to accelerate nonhomologous end-joining.

Authors:  Stuart L Rulten; Anna E O Fisher; Isabelle Robert; Maria C Zuma; Michele Rouleau; Limei Ju; Guy Poirier; Bernardo Reina-San-Martin; Keith W Caldecott
Journal:  Mol Cell       Date:  2011-01-07       Impact factor: 17.970

Review 5.  Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.

Authors:  Thomas Helleday; Helen E Bryant; Niklas Schultz
Journal:  Cell Cycle       Date:  2005-09-12       Impact factor: 4.534

6.  Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase.

Authors:  M Kameoka; K Ota; T Tetsuka; Y Tanaka; A Itaya; T Okamoto; K Yoshihara
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

7.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

Authors:  Z Q Wang; B Auer; L Stingl; H Berghammer; D Haidacher; M Schweiger; E F Wagner
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

9.  Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins.

Authors:  Ivan Ahel; Dragana Ahel; Takahiro Matsusaka; Allison J Clark; Jonathon Pines; Simon J Boulton; Stephen C West
Journal:  Nature       Date:  2008-01-03       Impact factor: 49.962

10.  A family of macrodomain proteins reverses cellular mono-ADP-ribosylation.

Authors:  Gytis Jankevicius; Markus Hassler; Barbara Golia; Vladimir Rybin; Martin Zacharias; Gyula Timinszky; Andreas G Ladurner
Journal:  Nat Struct Mol Biol       Date:  2013-03-10       Impact factor: 15.369

View more
  63 in total

1.  EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.

Authors:  Qiongzhu Dong; Yi Du; Hui Li; Chunxiao Liu; Yongkun Wei; Mei-Kuang Chen; Xixi Zhao; Yu-Yi Chu; Yufan Qiu; Lunxiu Qin; Hirohito Yamaguchi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2018-12-20       Impact factor: 12.701

Review 2.  PARP-1 and its associated nucleases in DNA damage response.

Authors:  Yijie Wang; Weibo Luo; Yingfei Wang
Journal:  DNA Repair (Amst)       Date:  2019-07-08

3.  Ubiquitin Modification by the E3 Ligase/ADP-Ribosyltransferase Dtx3L/Parp9.

Authors:  Chun-Song Yang; Kasey Jividen; Adam Spencer; Natalia Dworak; Li Ni; Luke T Oostdyk; Mandovi Chatterjee; Beata Kuśmider; Brian Reon; Mahmut Parlak; Vera Gorbunova; Tarek Abbas; Erin Jeffery; Nicholas E Sherman; Bryce M Paschal
Journal:  Mol Cell       Date:  2017-05-18       Impact factor: 17.970

4.  Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.

Authors:  Dong Zhou; Jinbin Xu; Cedric Mpoy; Wenhua Chu; Sung Hoon Kim; Huifangjie Li; Buck E Rogers; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2018-08-24       Impact factor: 2.408

5.  Genomic hallmarks of localized, non-indolent prostate cancer.

Authors:  Michael Fraser; Veronica Y Sabelnykova; Takafumi N Yamaguchi; Lawrence E Heisler; Julie Livingstone; Vincent Huang; Yu-Jia Shiah; Fouad Yousif; Xihui Lin; Andre P Masella; Natalie S Fox; Michael Xie; Stephenie D Prokopec; Alejandro Berlin; Emilie Lalonde; Musaddeque Ahmed; Dominique Trudel; Xuemei Luo; Timothy A Beck; Alice Meng; Junyan Zhang; Alister D'Costa; Robert E Denroche; Haiying Kong; Shadrielle Melijah G Espiritu; Melvin L K Chua; Ada Wong; Taryne Chong; Michelle Sam; Jeremy Johns; Lee Timms; Nicholas B Buchner; Michèle Orain; Valérie Picard; Helène Hovington; Alexander Murison; Ken Kron; Nicholas J Harding; Christine P'ng; Kathleen E Houlahan; Kenneth C Chu; Bryan Lo; Francis Nguyen; Constance H Li; Ren X Sun; Richard de Borja; Christopher I Cooper; Julia F Hopkins; Shaylan K Govind; Clement Fung; Daryl Waggott; Jeffrey Green; Syed Haider; Michelle A Chan-Seng-Yue; Esther Jung; Zhiyuan Wang; Alain Bergeron; Alan Dal Pra; Louis Lacombe; Colin C Collins; Cenk Sahinalp; Mathieu Lupien; Neil E Fleshner; Housheng H He; Yves Fradet; Bernard Tetu; Theodorus van der Kwast; John D McPherson; Robert G Bristow; Paul C Boutros
Journal:  Nature       Date:  2017-01-09       Impact factor: 49.962

Review 6.  Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.

Authors:  John L Silberstein; Maritza N Taylor; Emmanuel S Antonarakis
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

7.  Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

Authors:  Ann-Gerd Thorsell; Torun Ekblad; Tobias Karlberg; Mirjam Löw; Ana Filipa Pinto; Lionel Trésaugues; Martin Moche; Michael S Cohen; Herwig Schüler
Journal:  J Med Chem       Date:  2016-12-21       Impact factor: 7.446

8.  Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage.

Authors:  Xiangduo Kong; Gladys M S Cruz; Bárbara A Silva; Nicole M Wakida; Nima Khatibzadeh; Michael W Berns; Kyoko Yokomori
Journal:  J Vis Exp       Date:  2018-01-31       Impact factor: 1.355

9.  Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Authors:  Zhuo Zhang; Rajani Rajbhandari; Monica E Wielgos; Tiffiny S Cooper; Ling Zeng; Andres Forero; Francisco J Esteva; C Kent Osborne; Rachel Schiff; Albert F LoBuglio; Susan E Nozell; Eddy S Yang
Journal:  Mol Cancer Ther       Date:  2018-03-28       Impact factor: 6.261

10.  Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.

Authors:  Jiyong Liang; Lulu Wang; Chao Wang; Jianfeng Shen; Bojin Su; Anantha L Marisetty; Dexing Fang; Cynthia Kassab; Kang Jin Jeong; Wei Zhao; Yiling Lu; Abhinav K Jain; Zhicheng Zhou; Han Liang; Shao-Cong Sun; Changming Lu; Zhi-Xiang Xu; Qinghua Yu; Shan Shao; XiaoHua Chen; Meng Gao; Francois X Claret; Zhiyong Ding; Jian Chen; Pingsheng Chen; Michelle C Barton; Guang Peng; Gordon B Mills; Amy B Heimberger
Journal:  Cancer Immunol Res       Date:  2020-04-07       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.